FDA issued a Warning Letter to Raritan Pharmaceuticals, Inc. on 6/20/2017 for a previous inspection.
483 Raritan Pharmaceuticals Jan 2018

483 Raritan Pharmaceuticals Jan 2018

Guerlain Ulysse FDA$119.00 - Available Now

FDA investigators audited the Raritan Pharmaceuticals - East Brunswick, NJ, United States facility and issued inspectional observations (via FDA 483) on 08 Jan 2018.

Product details

  • Category: Human Drugs
  • Inspection end: 08 Jan 2018
  • Location: East Brunswick, United States
  • FEI: 3004083931
Add To Cart